techno-foxx
15 Feb 2020
Immunotheropy, cancer t cells and car-t news interview with Carl June about Cart T [link]
techno-foxx
03 Feb 2020
Coronavirus extract from on line article “During the original SARS outbreak, we found that the fatality rate was 10%,†says Vineet Menachery, an immunologist at the University of Texas Medical Branch who studies how coronaviruses affect aging immune systems. “But that jumped to 50% in people over the age of 50.†There was a similar pattern of fatalities with MERS in 2015. All three viruses—SARS, MERS, and now 2019-nCoV—fall within the category of coronaviruses, which get their names from the spiky crown of proteins on the viruses’ outer shell. So while we don’t have a firm fatality rate for older adults with 2019-nCoV, it’s likely that it’ll also be higher than in younger adults. techno fox the following reasons I think our technology might play a role? There are two reasons older adults are more susceptible to infections. First, seniors are more likely to have other chronic health conditions, like diabetes or chronic obstructive pulmonary disease, that make it harder for their bodies to cope with damage caused by a new pathogen. Every year, the majority of flu deaths are seen in people 65 or older. Second, the immune system changes with age—particularly in its ability to respond to coronaviruses. Unlike the flu virus, which does most of the damage to your body on its own, most of the symptoms from coronavirus infections actually come from the body’s immune response, Menachery says. Although he and his lab team are still characterizing these reactions, it seems like coronaviruses encourage older immune systems to kick in with extra inflammation, which can have a cascading effect.
paulchambersdps
03 Feb 2020
Coronavirus Hello Techno The immune system is at its strongest as a young adult, children’s immune systems aren’t fully developed.
techno-foxx
03 Feb 2020
Coronavirus sorry forgot to put my reasoning behind this idea, well children under 13 so far have not been effected by this virus, could this be because they have strongest immune system, whilst those over 60 have the highest death rate, which could also be linked to the poorest immune systems.
techno-foxx
03 Feb 2020
Coronavirus A new vaccine for this virus could be weeks or months away, could the immune system be boosted using our technology by extracting and multiplying virus fighting blood cells and then returning these millions of extra virus fighting cells to the human body to help fight off this virus.
techno-foxx
22 Jan 2020
Immunotheropy, cancer t cells and car-t news I have just had another thought, OXB also had a T-cell based vaccine still going through trials, what if the newly discovered T-cell could either work better as a base for this vaccine or turbo charge it by adding this new cell to the mix, again it looks like the perfect fit for Oxford Bio?
techno-foxx
22 Jan 2020
Immunotheropy, cancer t cells and car-t news This NEW cancer cell discovery might just be the perfect fit for Oxford Biomedica who have the right proven cell based technology to mass produce these T cells, this looks like the perfect partner to our Cart-t treatment, plus OXB technology for producing cells using our technology has also been through the US trials and approved by the FDA, OXB and CARDIFF Uni should get together to do this? The Telegraph Immune cell which kills most cancers discovered by accident by British... A new type of immune cell which kills most cancers has been discovered by accident by British scientists, in a finding which could herald a major breakthrough in treatment.
techno-foxx
20 Jan 2020
Novartis release good figures relating to Kymriah sale's [link]
d_gaser
28 May 2019
Novo invest £53.5 million in OXB Oxford Biomedica announces strategic investment by Novo Holdings A/S Oxford, UK – 28 May 2019: Oxford Biomedica plc (LSE:OXB) (“OXB†or “the Groupâ€), a leading gene and cell therapy group, today announces that Novo Holdings A/S (“Novo Holdingsâ€), has agreed to invest up to £53.5 million in the Group in return for new ordinary shares representing up to 10.1% of the outstanding shares after the capital increase (the “Transactionâ€).
techno-foxx
24 Feb 2019
Cancer vacine? medicalxpress.com Discovery of new 'checkpoint' points to new cancer immunotherapy option An international team involving Vanderbilt researchers has discovered that a new "checkpoint" protein on immune system cells is active in tumors, and that blocking it—in combination with other treatments—is a successful therapeutic approach in mouse...
techno-foxx
31 Jan 2019
Novartis release good figures relating to Kymriah sale's if you check, you will find this is not the only company that Novartis have bought in the hope of reducing costs to do the exact same thing you are pointing out on here with this deal, plus you did not address my point regarding new trials.
d_gaser
31 Jan 2019
Novartis release good figures relating to Kymriah sale's Techno fox I’m not suggesting things would change over night ,but I was concerned to read that Novartis have just brought out a manufacturing company called Cellforcure and they carry out a form of direct transfers of cell and gene material into the blood system see link . head lined CELLforCURE will produce innovative cancer CAR-T treatments for Novartis. Novartis announces that its innovative cancer CAR-T treatments will be produced in Les Ulis (Essonne), as proof of its commitment to France. www.cellforcure.com/news/cellforcure-will-produce-innovative-cancer-car-t-treatments-novartis/ 20 Dec '18 Novartis • Proposed acquisition builds on existing agreement with CellforCure for contract manufacturing of Novartis leading CAR-T cell therapy Kymriah® (tisagenlecleucel) and recent successful completion of technology transfer • If completed, this acquisition would bolster CAR-T cell therapy manufacturing capacity with potential to expand to other cell and gene therapies in Novartis pipeline • CellforCure would become wholly owned Novartis manufacturing facility, joining network of cell and gene sites including Morris Plains and Stein Basel, December 20, 2018 - Novartis today announced an offer to acquire CellforCure from LFB. CellforCure, a French company, is one of the first and largest contract development and manufacturing organizations (CDMO) producing cell and gene therapies in Europe. Under the proposed agreement, Novartis would acquire the share capital of CellforCure from LFB including the cell and gene manufacturing facility located in Les Ulis and therelated adjacent land. If the offer is accepted, CellforCure would become a wholly owned Novartis manufacturing site, joining the network of cell and gene therapy sites including Morris Plains, New Jersey, USA and Stein, Switzerland, where construction continues to progress as planned.
techno-foxx
31 Jan 2019
First child treated with oxford biomedca technlogy in UK BBC News Pioneering cancer therapy for first child An 11-year-old-boy with leukaemia is the first patient to get a personalised therapy paid for by the NHS.
techno-foxx
31 Jan 2019
Novartis release good figures relating to Kymriah sale's sorry when I said I could be wrong, I was being sarcastic, when in fact I am 100% correct in fact so far I believe our delivery system is the only one in which no deaths so far.
techno-foxx
31 Jan 2019
Novartis release good figures relating to Kymriah sale's now I could be wrong but would not these other ways of delivering this require new drug trials which could take years, plus the competition to our delivery technology is already used by our rivals in which so far has resulted in higher death rates than ours.
